ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Lucjan Stanislaw Wyrwicz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0808-6892; OpenAlex author ID A5054846836, A5112567836. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 18

Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 4

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746 ↗
Synergistic effects of calcium channel blockers and renin-angiotensin inhibitors with gemcitabine-based chemotherapy on the survival of patients with pancreati… Last author DOI 10.1007/s00432-024-05962-5 ↗
Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16233945 ↗
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Co-author DOI 10.1016/j.ejca.2022.12.009 ↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Leszek Kraj · 2 shared papers, 2024 · strength 0.47
- Paper Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16233945 ↗
- Paper Synergistic effects of calcium channel blockers and renin-angiotensin inhibitors with gemcitabine-based chemotherapy on… DOI 10.1007/s00432-024-05962-5 ↗
Łukasz Szymański · 2 shared papers, 2024 · strength 0.47
- Paper Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16233945 ↗
- Paper Synergistic effects of calcium channel blockers and renin-angiotensin inhibitors with gemcitabine-based chemotherapy on… DOI 10.1007/s00432-024-05962-5 ↗
Natalia Kluz · 1 shared paper, 2024 · strength 0.24
- Paper Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16233945 ↗
Andrzej M. Śliwczyński · 1 shared paper, 2024 · strength 0.23
- Paper Synergistic effects of calcium channel blockers and renin-angiotensin inhibitors with gemcitabine-based chemotherapy on… DOI 10.1007/s00432-024-05962-5 ↗
Maciej Słodkowski · 1 shared paper, 2024 · strength 0.23
- Paper Synergistic effects of calcium channel blockers and renin-angiotensin inhibitors with gemcitabine-based chemotherapy on… DOI 10.1007/s00432-024-05962-5 ↗
Marcus Bahra · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Katharina Tschoep · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Wolfgang Erwin Thasler · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Rainer Fietkau · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Pirus Ghadjar · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Rolf Dieter Issels · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Wolfram Trudo Knoefel · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Volker Heinemann · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Uwe Pelzer · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Helmut Oettle · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Jens Werner · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Stefan Hubert Boeck · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗
Christiane J. Bruns · 1 shared paper, 2023 · strength 0.11
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.